Commentary Open Access
Volume 6 | Issue 3 | DOI: https://doi.org/10.33696/cancerimmunol.6.089
A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies
Gennie L. Parkman1,2,*, Sheri L. Holmen2,3
- 1Department of Zoology, Weber State University, Ogden, Utah 84408, USA
- 2Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah 84112, USA
- 3Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah 84112, USA
Corresponding Author
Gennie L. Parkman, gennieparkman@weber.edu
Received Date: June 17, 2024
Accepted Date: July 30, 2024
Parkman GL, Holmen SL. A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies. J Cancer Immunol. 2024;6(3):92-99.
Copyright: © 2024 Parkman GL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Melanoma, AKT, PI3K, mTOR, Immune system
Recommended Articles
Role of PI3K/Akt/GSK-3 Pathway in Emesis and Potential New Antiemetics
Nausea and vomiting are protective defense mechanisms by which vomit competent species avoid ingestion of potentially toxic substances. More specifically, vomiting is the act of forceful expulsion of gastrointestinal contents through the mouth, whereas nausea is an unpleasant painless subjective feeling that one will imminently vomit.
Targeting the PI3K/AKT/mTOR/NFkB Axis in Ovarian Cancer
Ovarian cancer stands as the most lethal gynecologic malignancy and remains the fifth most common gynecologic cancer. Poor prognosis and low five-year survival rate are attributed to nonspecific symptoms at early phases along with a lack of effective treatment at advanced stages. It is thus paramount, that ovarian carcinoma be viewed through several lenses in order to gain a thorough comprehension of its molecular pathogenesis, epidemiology, histological subtypes, hereditary factors, diagnostic approaches, and methods of treatment.
M1 and M2 Macrophages Polarization via mTORC1 Influences Innate Immunity and Outcome of Ehrlichia Infection
Human monocytic ehrlichiosis (HME) is an emerging life-threatening tick-borne disease caused by the obligate intracellular bacterium Ehrlichia chaffeensis. HME is often presented as a nonspecific flu-like illness characterized by presence of fever, headache, malaise, and myalgia. However, in some cases the disease can evolve to a severe form, which is commonly marked by acute liver injury followed by multi-organ failure and toxic shock-like syndrome.
Presence of Elevated Interleukin – 6 (IL-6) in the Blood of COVID-19 Convalescent Patients (40 – 93 Days) Post Onset of Symptoms Could be an Indicator of Ongoing Activation of the Immune System
IL-6 concentrations rise with the onset of COVID-19 infection and is detected in 68% of patients on admission but is expected to reduce after the acute phase. IL-6 concentrations at time points: (2-7 days), (6-11 days), (11-15 days) and (13-20 days) after intensive care unit (ICU) admission showed the highest level of IL-6 concentrations at time point 2-7 days, we decided to characterize IL-6 concentrations in serum samples collected in the sera of COVID-19 convalescent patients (40 – 93 days) post onset of symptoms.
A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies
Cutaneous melanoma, a malignancy originating from melanocytes in the skin, is challenging to treat due to its aggressive nature and propensity to metastasize. Despite the advancement of multifaceted treatment interventions, including targeted therapy, immunotherapy, and cellular therapy, the five-year-survival for patients with stage IV melanoma is only ~30% [1-3]. BRAF activating mutations are the most common genetic alteration in melanoma, comprising ~50% of all cutaneous melanoma cases [4,5].